MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
DHR stock logo

DHR

Danaher Corporation

$187.07
-1.34
 (-0.71%)
Exchange:  NYSE
Market Cap:  132.403B
Shares Outstanding:  320M
Delayed data
Calculate DHR Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Diagnostics & Research
   
CEO:  Rainer Blair
Full Time Employees:  61000
Address: 
2200 Pennsylvania Avenue, NW
Washington
DC
20037-1701
US
Website:  https://www.danaher.com
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians’ offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/04/21 — 1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue23,890,00023,875,00024,568,000
Gross Profit14,034,00014,206,00014,970,000
EBITDA7,499,0007,276,0006,945,000
Operating Income5,279,0005,184,0005,137,000
Net Income4,764,0003,899,0003,614,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets84,488,00077,542,00083,464,000
Total Liabilities30,998,00027,992,00030,930,000
Total Stockholders Equity53,486,00049,543,00052,534,000
Total Debt19,536,00017,146,00018,418,000
Cash and Cash Equivalents5,864,0002,078,0004,615,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow7,164,0006,688,0006,416,000
Capital Expenditure-1,383,000-1,392,000-1,156,000
Free Cash Flow5,781,0005,296,0005,260,000
Net Income4,221,0003,899,0003,614,000
Net Change in Cash-131,000-3,786,0002,537,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)31,390,638.467Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)33,072,347.172Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)31,735,333.333Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)10,026,803.108Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)10,563,974.790Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)10,136,905.601Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)8,063,379.911Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)8,626,818.972Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)8,178,867.641Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)9,384,094.762Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)9,886,834.261Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)9,487,139.792Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)11.500Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)12.130Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)11.340Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)7Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
23.875B  ?P/S
 (TTM)
: 
5.26
?Net Income
 (TTM)
: 
3.899B  ?P/E
 (TTM)
: 
35.37
?Enterprise Value
 (TTM)
: 
143.225B  ?EV/FCF
 (TTM)
: 
27.07
?Dividend Yield
 (TTM)
: 
0.01  ?Payout Ratio
 (TTM)
: 
0.25
?ROE
 (TTM)
: 
0.07  ?ROIC
 (TTM)
: 
0.06
?Net Debt
 (TTM)
: 
15.068B  ?Debt/Equity
 (TTM)
: 
0.35
?P/B
 (TTM)
: 
2.46  ?Current Ratio
 (TTM)
: 
1.87

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
22.16Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates DHR intrinsic value between $105.71 – $154.44 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about DHR valuation

Is Danaher Corporation (DHR) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Danaher Corporation (DHR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is DHR a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether DHR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is DHR’s P/E ratio?

You can see DHR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for DHR?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is DHR a good long-term investment?

Whether DHR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

DHR

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.71
MARKETSnap

Trading Metrics:

Open: 186.87   Previous Close: 188.41
Day Low: 185.03   Day High: 188.18
Year Low: 160.93   Year High: 242.8
Price Avg 50: 180.86   Price Avg 200: 205.22
Volume: 355960   Average Volume: 4.512M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations
01-06-2026 14:00
SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations
SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools
01-06-2026 14:00
SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools
A Look at Danaher Corp (DHR) After 4.3% Gain -- GF Value $236.05 vs Price $180.63
28-05-2026 17:19
A Look at Danaher Corp (DHR) After 4.3% Gain -- GF Value $236.05 vs Price $180.63
Why Is Danaher (DHR) Down 7% Since Last Earnings Report?
21-05-2026 12:31
Why Is Danaher (DHR) Down 7% Since Last Earnings Report?
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?
20-05-2026 12:21
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?
Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
13-05-2026 17:10
Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read